CA2739948A1 - Traitement de l'infection par le virus de l'hepatite c avec une surexpression de micro-arn-196 - Google Patents

Traitement de l'infection par le virus de l'hepatite c avec une surexpression de micro-arn-196 Download PDF

Info

Publication number
CA2739948A1
CA2739948A1 CA2739948A CA2739948A CA2739948A1 CA 2739948 A1 CA2739948 A1 CA 2739948A1 CA 2739948 A CA2739948 A CA 2739948A CA 2739948 A CA2739948 A CA 2739948A CA 2739948 A1 CA2739948 A1 CA 2739948A1
Authority
CA
Canada
Prior art keywords
mirna
hcv
expression
cells
mimic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2739948A
Other languages
English (en)
Inventor
Herbert L. Bonkovsky
Weihong Hou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charlotte Mecklenburg Hospital
Original Assignee
Charlotte Mecklenburg Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital
Publication of CA2739948A1 publication Critical patent/CA2739948A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA2739948A 2008-10-08 2009-10-08 Traitement de l'infection par le virus de l'hepatite c avec une surexpression de micro-arn-196 Abandoned CA2739948A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10360908P 2008-10-08 2008-10-08
US61/103,609 2008-10-08
PCT/US2009/059944 WO2010042683A1 (fr) 2008-10-08 2009-10-08 Traitement de l'infection par le virus de l'hépatite c avec une surexpression de micro-arn-196

Publications (1)

Publication Number Publication Date
CA2739948A1 true CA2739948A1 (fr) 2010-04-15

Family

ID=41559924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2739948A Abandoned CA2739948A1 (fr) 2008-10-08 2009-10-08 Traitement de l'infection par le virus de l'hepatite c avec une surexpression de micro-arn-196

Country Status (10)

Country Link
EP (1) EP2352829A1 (fr)
JP (1) JP2012505233A (fr)
KR (1) KR20110065568A (fr)
CN (1) CN102257140A (fr)
AR (1) AR073800A1 (fr)
AU (1) AU2009302344A1 (fr)
BR (1) BRPI0914060A2 (fr)
CA (1) CA2739948A1 (fr)
MX (1) MX2011003813A (fr)
WO (1) WO2010042683A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2572329B1 (es) 2011-10-21 2017-08-24 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa y ribavirina pero no interferón, para uso en el tratamientodel vhc
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
BR112014005617A2 (pt) 2011-10-21 2017-06-13 Abbvie Inc tratamento de combinação (por exemplo, com abt-072 ou abt -333) de daas para uso no tratamento de hcv
WO2017189978A1 (fr) 2016-04-28 2017-11-02 Emory University Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées
CN110724734B (zh) * 2019-10-22 2020-06-16 北京恩泽康泰生物科技有限公司 含miRNA mimic的人造脂质体及其制备方法与应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942634A (en) * 1997-05-09 1999-08-24 Genzyme Corporation Cationic amphiphiles for cell transfections
WO2009029681A2 (fr) * 2007-08-27 2009-03-05 The Regents Of The University Of California Micro-arn utilisés pour inhiber la réplication virale

Also Published As

Publication number Publication date
EP2352829A1 (fr) 2011-08-10
WO2010042683A1 (fr) 2010-04-15
MX2011003813A (es) 2011-07-28
AR073800A1 (es) 2010-12-01
AU2009302344A2 (en) 2011-04-28
BRPI0914060A2 (pt) 2015-11-17
KR20110065568A (ko) 2011-06-15
CN102257140A (zh) 2011-11-23
JP2012505233A (ja) 2012-03-01
AU2009302344A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CN107075515B (zh) C/EBPα组合物和使用方法
US10041070B2 (en) MicroRNAs modulating the effect of glucocorticoid signaling
Moshiri et al. Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma
KR20100060018A (ko) 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
Wang et al. microRNA-20b contributes to high glucose-induced podocyte apoptosis by targeting SIRT7
CA2739948A1 (fr) Traitement de l'infection par le virus de l'hepatite c avec une surexpression de micro-arn-196
JP2008525029A (ja) 遺伝子サイレンシングに有用なｈｂｖおよびｈｃｖ保存配列
Zheng et al. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression
CN112941076B (zh) FXR靶向的saRNA及其应用
WO2018193902A1 (fr) Procédé d'activité antivirale contre le virus de l'hépatite b au moyen de micro-arn
WO2016192669A1 (fr) Procédé et médicament pour la perte de poids et pour la diminution de la glycémie et de la lipidémie par l'intermédiaire de mir-96, et utilisation associée
US20110117181A1 (en) Treating hepatitis c virus infection with over-expression of microrna-196
WO2018210259A1 (fr) Médicament permettant de réguler l'appétit et le poids corporel, et application associée
WO2017084610A1 (fr) Application de mir-183 ou d'un inhibiteur de celui-ci
JP2008541754A (ja) Ｈｃｖ特異的な低分子干渉ｒｎａおよびそれを含むｃ型肝炎の治療剤
US9850489B2 (en) Repressor on IFN-λ promoter and siRNA against GATA1, EVI1, and CRX to alter IFN-λ gene activity
WO2011074652A1 (fr) Acide nucléique capable d'inhiber l'expression de hif-2a
WO2014015824A1 (fr) Méthode de criblage de micro-arn dotés d'une fonction de désactivation d'un gène au niveau de la transcription et après la transcription
CN110652522B (zh) miR-2052在制备抗肝癌药物中的应用
KR101928427B1 (ko) 마이크로rna-497을 유효성분으로 포함하는 알코올성 간질환의 예방 또는 치료용 조성물 및 이의 스크리닝 방법
US9163238B2 (en) Repressor on IFN-λ promoter and siRNA against ZEB1 and BLIMP-1 to increase IFN-λ gene activity
JP2023108978A (ja) ＨＢＶ由来ｃｃｃＤＮＡの抑制剤、抑制方法、ＨＢＶ感染症用医療組成物、およびＨＢＶ感染症の治療方法
EP4244359A1 (fr) Déficience en b-spectrine (sptbn1) protégeant les souris contre une maladie du foie induite par un régime riche en graisse et le développement du cancer
KR20090002560A (ko) ＮＩＫ 유전자에 대한 ｓｉＲＮＡ 및 이를 포함하는 간질환치료제
Liu et al. MiR-203 is an Anti-Obese miRNA by Targeting ASBT

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20141008